Randomized Phase 2 Trial of Induction Treatment of Anti-PD-1 Pucotenlimab and EGFR-ADC MRG003 Versus EGFR-ADC Alone Followed by Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-SCCHN).
Latest Information Update: 13 May 2025
At a glance
- Drugs MRG 003 (Primary) ; Pucotenlimab (Primary) ; Cisplatin
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms IDEAL
Most Recent Events
- 13 May 2025 New trial record